{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:01:35Z","timestamp":1760954495198},"reference-count":20,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Multiple myeloma (MM) and primary systemic amyloidosis (AL) remain incurable disorders, and new treatments targeted to the malignant plasma cells are needed. Alemtuzumab is a humanized monoclonal antibody to CD52 and has activity in chronic lymphocytic leukemia. We examined the CD52 expression on CD45+ and CD45- plasma cell populations to evaluate the potential for using alemtuzumab for these disorders. Bone marrows from 61 patients (29 AL, 23 MM, and 9 MGUS [monoclonal gammopathies of undetermined significance]) were studied using 3-color (CD38\/45\/52) flow cytometry. Among those with MGUS, MM, and AL, 67%, 52%, and 35%, respectively, were positive for CD52 expression. The CD52 expression was predominantly confined to the clonal CD38+\/CD45+ plasma cell fraction with median expression of 68%, 88%, and 82% in MGUS, MM, and AL, respectively, compared with 18%, 6%, and 9% among the CD45- plasma cell population. Clinical trials are warranted in these diseases to learn the therapeutic benefit of anti-CD52 immunotherapy.<\/jats:p>","DOI":"10.1182\/blood-2002-12-3784","type":"journal-article","created":{"date-parts":[[2003,4,29]],"date-time":"2003-04-29T00:14:21Z","timestamp":1051575261000},"page":"1075-1077","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":42,"title":["Expression of CD52 on plasma cells in plasma cell proliferative disorders"],"prefix":"10.1182","volume":"102","author":[{"given":"Shaji","family":"Kumar","sequence":"first","affiliation":[{"name":"From the Department of Internal Medicine, Division of Hematology and the Department of Laboratory Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa K.","family":"Kimlinger","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Hematology and the Department of Laboratory Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Lust","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Hematology and the Department of Laboratory Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Donovan","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Hematology and the Department of Laboratory Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[{"name":"From the Department of Internal Medicine, Division of Hematology and the Department of Laboratory Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021223264381600_REF1","doi-asserted-by":"crossref","unstructured":"Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med.1997;336: 1657-1664.","DOI":"10.1056\/NEJM199706053362307"},{"key":"2020021223264381600_REF2","doi-asserted-by":"crossref","unstructured":"Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin.2002;52: 23-47.","DOI":"10.3322\/canjclin.52.1.23"},{"key":"2020021223264381600_REF3","doi-asserted-by":"crossref","unstructured":"Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med.1996;335: 91-97.","DOI":"10.1056\/NEJM199607113350204"},{"key":"2020021223264381600_REF4","unstructured":"Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol.1995;32: 45-59."},{"key":"2020021223264381600_REF5","doi-asserted-by":"crossref","unstructured":"Gertz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood. 1991;77: 257-262.","DOI":"10.1182\/blood.V77.2.257.257"},{"key":"2020021223264381600_REF6","doi-asserted-by":"crossref","unstructured":"Hale G, Xia MQ, Tighe HP, Dyer MJ, Waldmann H. The CAMPATH-1 antigen (CDw52). Tissue Antigens.1990;35: 118-127.","DOI":"10.1111\/j.1399-0039.1990.tb01767.x"},{"key":"2020021223264381600_REF7","doi-asserted-by":"crossref","unstructured":"Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood. 1993;82: 807-812.","DOI":"10.1182\/blood.V82.3.807.807"},{"key":"2020021223264381600_REF8","doi-asserted-by":"crossref","unstructured":"Hale G, Bright S, Chumbley G, et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood. 1983;62: 873-882.","DOI":"10.1182\/blood.V62.4.873.873"},{"key":"2020021223264381600_REF9","doi-asserted-by":"crossref","unstructured":"Hale G, Swirsky D, Waldmann H, Chan LC. Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone marrow transplantation. Br J Haematol.1985;60: 41-48.","DOI":"10.1111\/j.1365-2141.1985.tb07383.x"},{"key":"2020021223264381600_REF10","doi-asserted-by":"crossref","unstructured":"Rowan W, Tite J, Topley P, Brett SJ. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology. 1998;95: 427-436.","DOI":"10.1046\/j.1365-2567.1998.00615.x"},{"key":"2020021223264381600_REF11","doi-asserted-by":"crossref","unstructured":"Hale G, Dyer MJ, Clark MR, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet. 1988;2: 1394-1399.","DOI":"10.1016\/S0140-6736(88)90588-0"},{"key":"2020021223264381600_REF12","doi-asserted-by":"crossref","unstructured":"Hale G, Waldmann H. CAMPATH-1 monoclonal antibodies in bone marrow transplantation. J Hematother.1994;3: 15-31.","DOI":"10.1089\/scd.1.1994.3.15"},{"key":"2020021223264381600_REF13","doi-asserted-by":"crossref","unstructured":"Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99: 3554-3561.","DOI":"10.1182\/blood.V99.10.3554"},{"key":"2020021223264381600_REF14","doi-asserted-by":"crossref","unstructured":"Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol.2002;20: 3891-3897.","DOI":"10.1200\/JCO.2002.06.119"},{"key":"2020021223264381600_REF15","unstructured":"Lin P, Wilson CS, Owens R, Tricot G. Immunophenotype of 195 multiple myeloma (MM) analyzed by flow cytometry [abstract]. Blood. 2001;98: 300b."},{"key":"2020021223264381600_REF16","unstructured":"Huh Y, Kantarjian H, Pierce S, et al. Expression of CD52 in human hematopoietic malignancies [abstract]. Blood. 1998;92: 278b."},{"key":"2020021223264381600_REF17","doi-asserted-by":"crossref","unstructured":"Joshua D, Petersen A, Brown R, Pope B, Snowdon L, Gibson J. The labelling index of primitive plasma cells determines the clinical behaviour of patients with myelomatosis. Br J Haematol.1996;94: 76-81.","DOI":"10.1046\/j.1365-2141.1996.d01-1784.x"},{"key":"2020021223264381600_REF18","doi-asserted-by":"crossref","unstructured":"Schneider U, van Lessen A, Huhn D, Serke S. Two subsets of peripheral blood plasma cells defined by differential expression of CD45 antigen. Br J Haematol.1997;97: 56-64.","DOI":"10.1046\/j.1365-2141.1997.d01-2115.x"},{"key":"2020021223264381600_REF19","doi-asserted-by":"crossref","unstructured":"Ishikawa H, Mahmoud MS, Fujii R, Abroun S, Kawano MM. Proliferation of immature myeloma cells by interleukin-6 is associated with CD45 expression in human multiple myeloma. Leuk Lymphoma.2000;39: 51-55.","DOI":"10.3109\/10428190009053538"},{"key":"2020021223264381600_REF20","doi-asserted-by":"crossref","unstructured":"Asosingh K, De Raeve H, Croucher P, et al. In vivo homing and differentiation characteristics of mature (CD45-) and immature (CD45+)5T multiple myeloma cells. Exp Hematol.2001;29: 77-84.","DOI":"10.1016\/S0301-472X(00)00625-1"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/3\/1075\/1689098\/h81503001075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/3\/1075\/1689098\/h81503001075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T04:26:52Z","timestamp":1581568012000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/102\/3\/1075\/17297\/Expression-of-CD52-on-plasma-cells-in-plasma-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8,1]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,8,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-12-3784","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,8,1]]}}}